Status:
COMPLETED
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Lead Sponsor:
Synta Pharmaceuticals Corp.
Conditions:
AML
CML
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Males and females 18 years or older
- Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol
- Must have acceptable organ function during screening as defined in the protocol
- Exclusion Criteria
- Pregnant or breast-feeding women
- Patients must meet the washout periods for prior chemotherapies and radiation
- History of stroke within 6 months of treatment
- Poor venous access for study drug administration
- Treatment with chronic immunosuppressants
- Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
Exclusion
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00858572
Start Date
March 1 2009
End Date
February 1 2013
Last Update
September 18 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston, Massachusetts, United States, 02115
2
New York, New York, United States, 10065
3
San Antonio, Texas, United States, 78229